# Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

> **NCT00897533** · — · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 137 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **GENETIC:** gene mapping
- **GENETIC:** polymorphism analysis
- **OTHER:** diagnostic laboratory biomarker analysis
- **OTHER:** immunohistochemistry staining method

## Key facts

- **NCT ID:** NCT00897533
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-13
- **Primary completion:** 2008-04-13
- **Final completion:** 2008-04-13
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2017-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00897533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00897533, "Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00897533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*